← Leaderboards
Renee D Read
Emory University
$5,379,597
Attributed
$5,379,597
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,379,597 · 7
By mechanism
R01$3,411,567 · 2
R21$920,220 · 2
R00$735,796 · 1
K99$168,814 · 1
F32$143,200 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Dipali Sharma$3,976,187
- Sunil Singhal$10,554,167
- William Evans Mitch$8,588,029
- Chunhai Charlie Hao$5,475,176
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionResponseCellsPathway InteractionsTumorOverexpressionGrowthProteinsGeneticMigrationMutantPharmaceutical PreparationsMutationApoptosisPhosphotransferasesMediatingSignal PathwayReceptor Protein-Tyrosine KinasesMouse ModelResistanceNeoplastic CellInsightNeurogliaGlioma
Grant awards (21)
Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma$582,634
R01 · FY2025 · NS · contact PI
Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma$560,145
R01 · FY2024 · NS · contact PI
Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma$577,469
R01 · FY2023 · NS · contact PI
Human Organoid Models for Pediatric High-Grade Gliomas$430,375
R21 · FY2023 · NS · contact PI
MET kinase fusions in pediatric glioblastoma$195,625
R21 · FY2023 · NS · contact PI
MET kinase fusions in pediatric glioblastoma$37,560
R21 · FY2023 · NS · contact PI
MET kinase fusions in pediatric glioblastoma$234,750
R21 · FY2022 · NS · contact PI
MET kinase fusions in pediatric glioblastoma$21,910
R21 · FY2022 · NS · contact PI
Mechanisms of RIOK2 function in glioblastoma$337,669
R01 · FY2021 · NS · contact PI
Mechanisms of RIOK2 function in glioblastoma$337,995
R01 · FY2020 · NS · contact PI
Mechanisms of RIOK2 function in glioblastoma$338,291
R01 · FY2019 · NS · contact PI
Mechanisms of RIOK2 function in glioblastoma$338,560
R01 · FY2018 · NS · contact PI
Mechanisms of RIOK2 function in glioblastoma$338,804
R01 · FY2017 · NS · contact PI
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration$246,511
R00 · FY2014 · NS · contact PI
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration$240,285
R00 · FY2013 · NS · contact PI
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration$249,000
R00 · FY2012 · NS · contact PI
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration$85,335
K99 · FY2010 · NS · contact PI
Revealing new regulators of EGFR-P13K driven glioma proliferation and migration$83,479
K99 · FY2009 · NS · contact PI
Wnt signaling via the Drl axon guidance receptor$50,428
F32 · FY2007 · NS · contact PI
Wnt signaling via the Drl axon guidance receptor$48,796
F32 · FY2006 · NS · contact PI
Wnt signaling via the Drl axon guidance receptor$43,976
F32 · FY2005 · NS